<DOC>
	<DOCNO>NCT02676076</DOCNO>
	<brief_summary>The purpose study evaluate superiority CHF 5993 100/6/12.5 µg pMDI ( fix combination extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronum bromide ) versus CHF 1535 100/6 µg pMDI ( fix combination extrafine beclometasone dipropionate plus formoterol fumarate ) , term lung function parameter rate exacerbation , well assess safety health economics outcome .</brief_summary>
	<brief_title>TRIple asthMA With uncontRolled pAtient Medium streNgth ICS + LABA</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>History asthma ≥ 1 year diagnose 40 year old Uncontrolled asthma double therapy medium dose Inhaled CorticoSteroid ( ICS ) combination Longacting beta2 Agonist ( LABA ) ACQ7 ( Asthma Control Questionnaire ) ≥1.5 Prebronchodilator FEV1 &lt; 80 % predict normal value Positive reversibility test At least 1 documented asthma exacerbation previous year Pregnant lactating woman Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) Patients asthma exacerbation respiratory tract infection 4 week prior screen Current exsmokers ( &gt; = 10 pack year ) Any change dose , schedule formulation ICS + LABA combination 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>asthma , anticholinergic , triple combination</keyword>
</DOC>